Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Oakley, NC
Brian Dealt Oakley, Varina, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20100058308 | CENTRAL PROVIDER AND SATELLITE PROVIDER UPDATE AND DIAGNOSIS INTEGRATION TOOL - The present invention generally relates to computer systems and methods of integrating a central system and a satellite system for automatically updating software and providing diagnostics for a product system to be shipped to an end customer. | 03-04-2010 |
David M. Oakley, Holly Springs, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20100159001 | Extended-Release Pharmaceutical Formulations - The present invention provides matrix-forming, sustained-release pharmaceutical formulations comprising four primary components: i) an effective amount of at least one drug substance; ii) at least one pharmaceutically acceptable, water-swellable, pH independent polymer; iii) at least one pharmaceutically-acceptable, anionic, pH dependent polymer; and (iv) a pharmaceutically-acceptable polymer selected from the group consisting of a) at least one pharmaceutically-acceptable cationic polymer; and b) at least one pharmaceutically acceptable hydrocolloid. The present formulations can be used with compounds having a wide range of solubilities as well as compounds characterized as having hydrophobic or hydrophilic characteristics. | 06-24-2010 |
| 20100160363 | EXTENDED-RELEASE PHARMACEUTICAL FORMULATIONS - The present invention provides matrix-forming, sustained-release pharmaceutical formulations comprising four primary components: i) an effective amount of at least one drug substance; ii) at least one pharmaceutically acceptable, water-swellable, pH independent polymer; iii) at least one pharmaceutically-acceptable, anionic, pH dependent polymer; and (iv) a pharmaceutically-acceptable polymer selected from the group consisting of a) at least one pharmaceutically-acceptable cationic polymer; and b) at least one pharmaceutically acceptable hydrocolloid. The present formulations can be used with compounds having a wide range of solubilities as well as compounds characterized as having hydrophobic or hydrophilic characteristics. | 06-24-2010 |
Michael Alan Oakley, Durham, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20100148877 | INTEGRATED POWER AMPLIFIERS FOR USE IN WIRELESS COMMUNICATION DEVICES - An integrated power amplifier can include a carrier amplifier, where the carrier amplifier is connected to a first quarter wave transformer at the input of the carrier amplifier. In addition, the power amplifier can further include at least one peaking amplifier connected in parallel with the carrier amplifier; a first differential combining structure, where the first combining structure includes a first plurality of quarter wave transformers that are configured to combine respective first differential outputs of the carrier amplifier in phase to generate a first single-ended output signal, and a second differential combining structure, where the second combining structures includes a second plurality of quarter wave transformers that are configured to combine respective second differential outputs of the at least one peaking amplifier in phase to generate a second single-ended output signal, where the first single-ended output signal and the second single-ended output signal are combinable in-phase to provide an overall output. | 06-17-2010 |
Robert H. Oakley, Durham, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20090069371 | ISOQUINOLINE COMPOUNDS - Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided. | 03-12-2009 |
| 20090075314 | SINGLE-CELL BIOSENSOR FOR THE MEASUREMENT OF GPCR LIGANDS IN A TEST SAMPLE - The present invention is related to the detection of GPCR ligands in a test sample by using a single cell biosensor expressing a GPCR. Preferably, the test sample is derived from a biological or environmental sample. This invention may be used to detect the presence of a disease or to detect the presence of a harmful agent in the environment. Included in the present invention is an array of biosensors that detect ligands of various GPCRs. | 03-19-2009 |
| 20090081652 | Constitutively Translocating Cell Line - The present invention relates to agonist-independent methods of screening for compounds that alter GPCR desensitization. Included in the present invention are cell lines containing GRKs, in which GPCRs are desensitized in the absence of agonist; the GRKs may be modified. The present invention relates to methods to determine if a GPCR is expressed at the plasma membrane, and if the GPCR has an affinity for arrestin. Modified GPCRs which have increased arrestin affinity are included in the present invention. These modified GPCRs are useful in methods to screen for compounds that alter desensitization, including both the agonist-independent methods and agonist-dependent methods described herein. | 03-26-2009 |
| 20090082410 | CONSTITUTIVELY TRANSLOCATING CELL LINE - The present invention relates to agonist-independent methods of screening for compounds that alter GPCR desensitization. Included in the present invention are cell lines containing GRKs, in which GPCRs are desensitized in the absence of agonist; the GRKs may be modified. The present invention relates to methods to determine if a GPCR is expressed at the plasma membrane, and if the GPCR has an affinity for arrestin. Modified GPCRs which have increased arrestin affinity are included in the present invention. These modified GPCRs are useful in methods to screen for compounds that alter desensitization, including both the agonist-independent methods and agonist-dependent methods described herein. | 03-26-2009 |
| 20100093790 | ISOQUINOLINE COMPOUNDS - Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided. | 04-15-2010 |